（原标题：奥地利前总理：中欧合作需加强各层面交流｜全球财经连线） 在许塞尔看来，科学家之间、学生之间的所有交流，以及各类民间往来都值得欢迎。"民众与民众、科 学家与科学家、商界人士与商界人士之间的对话，这些交流都至关重要。" 南方财经 21世纪经济报道记者杨雨莱 广州报道 在他看来，这样的变化确实令人瞩目。但他同时强调，相比过往成就，大家更该关注未来，包括未来的 挑战与合作机遇。"生物科学很重要，量子力学相关领域也极具潜力。"许塞尔举例，奥地利诺贝尔物理 学奖得主安东·蔡林格就经常和中国的朋友、合作伙伴开展深度合作。 2025年"读懂中国"国际会议期间，奥地利前总理沃尔夫冈·许塞尔（Wolfgang Schüssel）在与南方财经记 者谈及中欧关系时，直言自己就喜欢用数据说话。 许塞尔表示，"50年前我们就开始和中国做贸易了，那时候贸易额并不高，而如今欧中双边贸易额已经 大约达到8000亿欧元。" ...

Group 1 - The flu season in China may arrive earlier this year, with a higher number of infections expected due to a different circulating strain, primarily H3N2, compared to last year's H1N1 strain, leading to lower immunity in the population [1] - The treatment options for influenza include symptomatic treatment, antiviral therapy, and traditional Chinese medicine, with antiviral drugs such as neuraminidase inhibitors, RNA polymerase inhibitors, and hemagglutinin inhibitors being highlighted [1] - There is a recommendation to pay attention to the market for antiviral drugs, respiratory disease medications, and flu vaccines [1] Group 2 - The vaccine ETF (159643) tracks the vaccine biotechnology index (980015), which selects listed companies involved in vaccine research, production, biotechnology, and life sciences tools and services to reflect the overall performance of the bioproducts and life sciences sector [1] - The index components focus on innovative drug development and disease prevention, showcasing the technological development trends and investment value in the bioscience industry [1]

Core Viewpoint - The "AI Augmented Biology" conference aims to explore the integration of artificial intelligence with biological sciences, facilitating groundbreaking discoveries and advancements in the field [4]. Group 1: Conference Details - The conference is organized by Nanjing University, the Chinese Biophysics Society, and several prestigious journals including Nature and Nature Biotechnology [2]. - It will take place from October 22 to 24, 2025, in Nanjing, with both online and offline participation [2]. - The agenda includes sessions on the interface of AI and biomedicine, AI in the multi-omics era, and decoding the language of molecules [5]. Group 2: Topics of Discussion - Key topics will include multimodal data mining, protein engineering, molecular and cellular engineering, and the application of large language models to understand complex biological systems and diseases [4]. - The conference will feature important milestones and breakthroughs in AI technology as applied to biological research [4]. Group 3: Editorial Participation - Editors from the Nature series journals will be present, providing opportunities for attendees to engage with them [5]. - Notable editors include Cheng Qian from Nature Communications and Angela Eggleston from Nature [5][6]. Group 4: Accommodation Information - Recommended hotels include Nanjing Zijin Mountain Villa with room rates starting at 450 RMB for a double room [14]. - Alternative accommodation is available at Jiangsu Conference Center, approximately 20 minutes from the venue, with rates starting at 380 RMB [14].

Summary of the Conference Call for 康龙化成 (Crown Bioscience) Q1 2025 Company Overview - 康龙化成 reported a revenue of 30.96 billion CNY in Q1 2025, representing a year-on-year growth of 15.4% [2][3] - The company maintains its revenue growth guidance for 2025 at 10% to 15% and expects to continue generating positive free cash flow [2][9] Key Financial Performance - The adjusted net profit for Q1 2025 was 3.49 billion CNY, a year-on-year increase of 3.1%, while the net profit attributable to shareholders was 3.06 billion CNY, up 32.5% [3][4] - The laboratory services segment generated 18.57 billion CNY, with a gross margin of 45.5%, up 1.4 percentage points [2][5] - The small molecule CDMO services segment reported revenue of 6.93 billion CNY, with a gross margin of 30.4%, an increase of 2.5 percentage points [2][5] - Clinical services revenue was 4.47 billion CNY, with a gross margin of 11.8%, up 2.5 percentage points [2][5] - The revenue from large molecule and cell & gene therapy services was 99 million CNY, showing a year-on-year growth of 7.9% [2][5] Revenue Breakdown by Region and Client Type - Revenue from Chinese laboratories and factories grew by 15.7%, accounting for 88% of total revenue; overseas revenue increased by 18.3%, making up 12% [2][6] - North American client revenue rose by 16.8%, representing 65% of total revenue; European client revenue increased by 26%, accounting for 18% [2][6] Order Growth and Market Trends - New orders maintained a double-digit growth of over 10% in Q1 2025, continuing the trend from the previous year [2][7] - The CMC business is focused on early clinical stages, with expectations for several large projects to advance into later stages, which will enhance CMC revenue and overall performance [4][23] Strategic Initiatives and Future Outlook - The company is investing in advanced technologies in the biosciences field, including 3D cell culture and organ-on-a-chip models, to stay at the forefront of industry developments [4][12] - The company anticipates that the adjusted net profit growth will accelerate from Q2 2025 onwards as operational efficiencies improve [3][4] - The overall market for laboratory services and biosciences is expected to continue its recovery, with double-digit growth anticipated in both sectors [9][20] Challenges and Considerations - The company faces challenges related to increased operational costs and depreciation due to new capacity coming online in 2024 [4][3] - The impact of geopolitical factors, such as tariffs and the IRA Act, on client R&D and production needs is being monitored, but the company remains optimistic about its growth trajectory [14][19] Conclusion - 康龙化成's Q1 2025 performance reflects strong growth across its segments, with a positive outlook for the remainder of the year, driven by strategic investments and a robust order pipeline [29]